The new science of personalized vaccines Ofer Levy

Transcriber: Ivana Korom
Reviewer: Krystian Aparta

It is hard to overstate
the beneficial effects of immunization.

According to the US
Centers for Disease Control,

US children born over the last 20 years –

for those children, vaccines will prevent
greater than 322 million illnesses,

greater than 21 million hospitalizations

and greater than 730,000 deaths,

with the societal cost savings
of nearly 1.4 trillion dollars.

Those are big numbers.

But let’s zoom in
and look at a particular example.

Vaccines have nearly eliminated

a bacterial infection
called Haemophilus influenzae.

This bacterium
used to infect young infants

causing bloodstream infections,

pneumonia, meningitis, death

or permanent disability.

As a young pediatrician,
I saw a few cases.

You folks probably have never
heard of this disease,

because vaccines have been so effective.

You could see in the graph on the right

that since the introduction of vaccines,

the incidence of Haemophilus
bacterial infections

has plummeted like a rock,
and it’s nearly vanished.

So vaccines are generally a success story.

But we also face challenges.

For one, for most vaccines,
we need to give multiple doses

to achieve or maintain protection.

The scientific community is working
on developing single-shot vaccines.

Imagine being able to get only one
influenza shot your whole life

and not having to get
a seasonal flu vaccine.

Certain microbes
are difficult to immunize against.

A classic example is human
immunodeficiency virus, or HIV.

The need is urgent,
progress is being made;

we’re not there yet.

Another critical element
in vaccine research right now

is optimizing vaccines
for the most vulnerable among us,

the very young and the elderly.

And this is an active area of research.

Finally, one of the biggest challenges
we unfortunately face right now

are anti-vax attitudes.

In fact, it’s alarming that over 100,000
infants and children in the United States

have not received any vaccines,

and that number is growing.

In fact, the World Health
Organization, or WHO,

has declared anti-vax attitudes

as one of the 10 most important
threats to human health

in the world today.

This graphic illustrates
the spread of anti-vax sentiment

in the state of California,

from the year 2000 to 2013,

by looking at the percentage
of public kindergarten students

who claim the personal exemption
against immunization.

Anti-vax sentiment is on the rise,

and it has very real consequences.

Many of you may be aware of the fact

that we’re seeing infections
that we thought we conquered long ago

coming back.

Measles outbreaks have been reported
in multiple US states.

And many have forgotten,

but measles is very
infectious and dangerous.

Just a few viral particles
can infect an individual.

And there have been even reports

at sporting events
and at an Olympic stadium

where the virus, through the air,
travels long distances

and infects a vulnerable
person in the crowd.

In fact, if I had
a measles cough right now,

(Coughs)

somebody in the back
of this auditorium could get infected.

And this has had
very real-world consequences.

Just a few months ago,

an airline stewardess
contracted measles on a flight,

the virus entered her brain
and caused encephalitis,

and she died.

So people are now dying
due to this anti-vax sentiment.

I do want to take a few minutes

to address those
who don’t believe in vaccines

and who resist vaccines.

As a pediatrician who receives
my yearly flu vaccination,

as a parent of three children

who have been vaccinated according
to the recommended schedule,

and as a pediatric infectious
disease consultant

who has taken care
of young children with meningitis

that would have been preventable
had their parents accepted immunization,

this is a personal matter to me.

Let’s take a look
at who is going to pay the price

if we start dialing back the amount
of vaccination in our society.

This graph depicts, on the Y axis,

the number of individuals
dying of infection in the world.

And on the X axis,

the age of the individuals who are dying.

And as you can see,
it’s very much a U-shaped distribution,

and it’s particularly stark
in the very young ages.

So vaccines shield
the very young from infection.

And if we want to talk, my friends,
about what vaccines cause,

because there’s a lot of speculation,

unfounded speculation on the internet,
of what vaccines cause,

vaccines cause adults, OK?

That’s what they cause.

And the other thing that they cause
is for elderly individuals to live longer.

Because they are shielded
against influenza

and other killers of the elderly.

Now, let’s talk a little bit

about how we can improve
vaccines even further.

We can create vaccines that can immunize
the most vulnerable among us

and perhaps even vaccines
that protect with single shots.

Let me go over a little bit
of the immunology.

In the top panel, what you see
is a simple vaccine.

All vaccines contain
something called an antigen.

The antigen is like a piece
of a germ, of a microbe,

that your body remembers, right?

It forms antibodies
and those antibodies can protect you.

So those kind of vaccines
can induce an immune response,

but as you see here,

that immune response
tends to go up and back down,

and you need to get another dose
and another dose

to maintain protection.

What can we do?

We and other scientists around the world

are finding molecules
that can boost a vaccine response.

Those are called adjuvants,

from the Latin “adjuvare,” to help or aid.

Adjuvants are molecules
we might add to a vaccine

to get a stronger response.

And in the presence of the adjuvant,
depicted here in red,

you have a much more profound
activation of the white blood cells

of your immune system,

and generate a much more
profound immune response,

with much higher antibody
levels, more rapidly,

and that lasts a long time
for durable immunity.

Interestingly, these adjuvants
have different effects

depending on the age or other demographic
factors of the individual.

Which brings me to the notion
of precision vaccines.

This is the idea that we will take
precision medicine –

you know what precision
medicine is, right,

that’s the idea that populations may vary

in their response
to a particular medicine –

and apply that to vaccines.

Right?

And here in Boston Children’s Hospital

at the Precision Vaccines
Program I direct,

we have five approaches,
stepwise approaches we take,

to build precision vaccines

that are tailored
to vulnerable populations.

Number one,

we need to understand
what the attitude of a given population is

towards a vaccine.

You could build the most
sophisticated vaccine in the world,

but if nobody wants to take it,
you’re going nowhere.

Number two,

we have to think
of the route of immunization.

Most vaccines are intramuscular, or IM,

but there are others,
intranasal, oral and others.

Then, as I just described to you,
vaccines have components.

All vaccines have an antigen,

that’s the part of the microbe
that your body remembers,

that you might make antibodies
or cell-mediated immunity against.

And we might add an adjuvant,
as we talked about,

to boost an immune response.

But guess what?

There are many different
antigens to choose from

and many different adjuvants.

How are we going to make that decision?

And the menu of these keeps growing.

So on our team,

we’ve developed ways
to test vaccines outside the body –

in Latin, that’s “in vitro” –

in a tissue culture dish.

So we use tissue engineering
with blood cells

to immunize outside the body

and study the effect of the vaccine

against, for example, infants
or elderly individuals or others.

And if you think about it,
this is critical,

because if you look at all the infections
we want to build vaccines against,

like Zika virus and Ebola virus
and HIV and others,

all the candidate antigens,

all the candidate adjuvants,

all the different populations,

it’s going to be impossible to do
large, phase III clinical trials

for every combination.

This is where we think being able
to test vaccines outside the body

can make a big difference
to accelerate vaccine development.

And finally, this whole effort
is to drive an immune response

that will protect against
that particular pathogen,

getting antibodies and other cells
to defend the body.

We are also using additional
innovative approaches

to bring the most cutting-edge science
to vaccine development.

We’re taking a deeper dive
as to how current vaccines protect.

We’ve formed an international consortium

to study how hepatitis B vaccine
protects newborns

from hepatitis B infection.

And to do this,

we’ve developed a technique
called small sample, big data.

We can get a tiny little drop
of baby blood before immunization,

and take a tiny little drop
after immunization,

and we can measure the inventory
of all the cells,

and all the genes and all the molecules
in that drop of blood,

and we can compare after the vaccine

to before the vaccine in that same baby

and understand in a deep way

exactly how that successful
vaccine protects.

And those lessons we can use
to build the next vaccines in the future.

So this diagram is really illustrating
a tiny drop of blood

yielding huge amounts of information,

tens of thousands of analytes,

and that hairball is meant to depict
the gene pathways that are turned on

and the molecular pathways
that are turned on.

So much more to come on that,
and very exciting science.

So we are partnering
with scientists around the world

to bring all these new technologies
to invigorate vaccine development

in a Precision Vaccines network.

We are going to advance
personalized vaccines

for vulnerable populations
around the world.

Our team includes scientists,
technical experts and physicians.

And we’re developing vaccines
against infectious diseases

like pertussis, which is whooping cough.

We have a whooping cough vaccine,

but it requires multiple doses,

and the immunity keeps dropping.

We want to develop a single-shot
pertussis vaccine.

We’re working on a vaccine
for respiratory syncytial virus,

the number one cause of infant
hospitalization in the United States.

A better vaccine against influenza,

and, of course, HIV.

We’re also looking at vaccines
against cancer, allergy

and, interestingly, opioid overdose.

So, this is my final message to you.

Vaccines protect you and your loved ones

and the people around you.

Not only do they protect you
against infection,

they prevent you
from spreading it to others.

Get immunized.

Scientific progress is fragile
and can be lost.

We must foster accurate
and respectful public dialogue.

And finally, we’re on the verge
of great things,

a new era of vaccination.

We’ve just scratched the surface
of what can be accomplished.

Please advocate for this research.

Thank you.

(Applause)

抄写员:Ivana Korom
审稿人:Krystian Aparta

免疫接种的有益效果怎么强调都不为过。

根据美国
疾病控制中心的数据,

过去 20 年出生的美国儿童——

对于这些儿童而言,疫苗将预防
超过 3.22 亿例疾病、

超过 2100 万例住院治疗

和超过 730,000 例死亡

,社会成本
节省近 1.4万亿美元。

这些都是很大的数字。

但让我们
放大来看一个特定的例子。

疫苗几乎消除

了一种
称为流感嗜血杆菌的细菌感染。

这种细菌
用于感染幼儿,

导致血流感染、

肺炎、脑膜炎、死亡

或永久性残疾。

作为一名年轻的儿科医生,
我看过一些案例。

你们可能从未
听说过这种疾病,

因为疫苗非常有效。

你可以在右图

中看到,自从疫苗问世以来

,嗜血
杆菌感染

的发病率像石头一样暴跌
,几乎消失了。

所以疫苗通常是一个成功的故事。

但我们也面临挑战。

其一,对于大多数疫苗,
我们需要给予多剂

以达到或维持保护。

科学界正
致力于开发单针疫苗。

想象一下,您一生只能接种一针
流感疫苗

,而不必
接种季节性流感疫苗。

某些
微生物很难免疫。

一个典型的例子是人类
免疫缺陷病毒或 HIV。

需求迫切,
正在取得进展;

我们还没有。

目前疫苗研究的另一个关键要素

是优化
针对我们当中最脆弱的人群

、非常年轻和老年人的疫苗。

这是一个活跃的研究领域。

最后,
不幸的是,我们现在面临的最大挑战之一

是反vax态度。

事实上,令人震惊的是,美国有超过 100,000 名
婴儿和儿童

没有接种任何疫苗,

而且这个数字还在增长。

事实上,
世界卫生组织或 WHO

已宣布反疫苗态度

为当今世界对人类健康的 10 大最重要
威胁

之一。

该图通过查看声称个人免疫接种豁免的公立幼儿园学生的百分比

,说明了

从 2000 年到 2013 年,加利福尼亚州

反疫苗情绪的蔓延。

反vax情绪正在上升,

并且产生了非常真实的后果。

你们中的许多人可能都知道

,我们认为我们很久以前就已经征服的感染

正在卷土重来。

美国多个州报告了麻疹疫情。

许多人已经忘记了,

但麻疹非常具有
传染性和危险性。

只有少数病毒颗粒
可以感染一个人。

甚至有报道称,

在体育赛事
和奥林匹克体育场

,病毒通过空气
传播很远,

并感染
人群中的弱势群体。

事实上,如果我
现在有麻疹咳嗽,

(咳嗽)

这个礼堂后面的人可能会被感染。

这已经产生了
非常现实的后果。

就在几个月前,

一名空姐
在一次航班上感染了麻疹

,病毒进入她的大脑
并导致脑炎

,她死了。

因此,
由于这种反疫苗情绪,人们现在正在死亡。

我确实想花几分钟时间

来解决
那些不相信疫苗

和抵制疫苗的人。

作为一名接受
我每年流感疫苗接种的儿科医生,

作为


按照建议的时间表接种疫苗的三个孩子的父母,

以及作为一名儿科
传染病顾问

,他曾照顾
患有脑膜炎的幼儿

,如果他们的父母本可以预防这种疾病
接受免疫接种,

这是我个人的事。

让我们看看

如果我们开始减少
社会中的疫苗接种量,谁将为此付出代价。

该图在 Y 轴上描绘

了世界上死于感染的人数。

在 X 轴上

,是垂死个体的年龄。

正如你所看到的,
它是一个非常 U 形的分布,

在非常年轻的时候尤其明显。

因此,疫苗可以
保护非常年轻的人免受感染。

我的朋友们,如果我们想
谈谈疫苗会导致什么,

因为互联网上有很多猜测,

没有根据的猜测
,关于疫苗会导致什么,

疫苗会导致成年人,好吗?

这就是他们造成的。

他们造成的另一件事
是让老年人活得更久。

因为它们可以
抵御流感

和其他老年人的杀手。

现在,让

我们谈谈如何
进一步改进疫苗。

我们可以研制出可以
为我们当中最脆弱的人免疫的

疫苗,甚至可以研制
出单次注射就可以保护的疫苗。

让我回顾
一下免疫学。

在顶部面板中,您看到的
是一种简单的疫苗。

所有疫苗都含有
一种叫做抗原的物质。

抗原就像
一块细菌,一种微生物

,你的身体会记住,对吧?

它形成抗体
,这些抗体可以保护你。

所以这类疫苗
可以诱导免疫反应,

但正如你在这里看到的

那样,免疫反应
往往会上升和下降

,你需要再注射一剂
和另一剂

来维持保护。

我们能做什么?

我们和世界各地的其他科学家

正在寻找
可以促进疫苗反应的分子。

这些被称为佐剂,

来自拉丁语“adjuvare”,用于帮助或帮助。

佐剂是
我们可以添加到疫苗中

以获得更强反应的分子。

在有佐剂存在的情况下,
这里用红色描绘,

你的免疫系统的白细胞会被更深入地
激活

并产生更
深刻的免疫反应,

抗体水平更高
,速度更快,

而且 持续很长时间
以获得持久的免疫力。

有趣的是,这些佐剂
具有不同的效果,

具体取决于个体的年龄或其他人口统计
因素。

这让我想到
了精准疫苗的概念。

这就是我们将采用
精准医学的想法——

你知道精准
医学是什么,对,

这就是人们对特定药物的反应可能不同的想法

——

并将其应用于疫苗。

对?

在我指导的波士顿儿童医院

的精准疫苗
项目中,

我们有五种方法,
我们采取逐步的方法

来制造

针对弱势群体的精准疫苗。

第一,

我们需要
了解特定人群

对疫苗的态度。

你可以制造世界上最
先进的疫苗,

但如果没有人愿意服用,
你将无处可去。

第二,

我们必须
考虑免疫途径。

大多数疫苗是肌肉注射或 IM,

但也有其他疫苗,
鼻内、口服等。

然后,正如我刚刚向您描述的那样,
疫苗具有成分。

所有疫苗都有一种抗原,


是你的身体记忆的微生物的一部分

,你可能会产生抗体
或细胞介导的免疫。

正如我们所说,我们可能会添加一种佐剂

来增强免疫反应。

但猜猜怎么了?

有许多不同的
抗原可供选择,

也有许多不同的佐剂可供选择。

我们将如何做出这个决定?

这些菜单不断增长。

因此,在我们的团队中,

我们开发了
在体外测试疫苗的方法——

在拉丁语中,这是“体外”——

在组织培养皿中。

因此,我们使用
带有血细胞的组织工程

在体外进行免疫,

并研究疫苗

对婴儿
或老年人或其他人的影响。

如果你仔细想想,
这很关键,

因为如果你看看
我们想要研制疫苗的所有感染,

比如寨卡病毒、埃博拉病毒
和 HIV 等,

所有候选抗原,

所有候选佐剂,

所有不同的 人群中,

不可能对每种组合进行
大型 III 期临床试验

这就是我们认为能够
在体外测试疫苗

可以
对加速疫苗开发产生重大影响的地方。

最后,这整个努力
是推动免疫反应

,以保护身体
免受特定病原体的侵害,

获得抗体和其他细胞
来保护身体。

我们还使用其他
创新

方法将最前沿的科学技术
引入疫苗开发。

我们正在更
深入地研究当前疫苗的保护方式。

我们成立了一个国际联盟

来研究乙型肝炎疫苗如何
保护新生儿

免受乙型肝炎感染。

为此,

我们开发了一种
称为小样本、大数据的技术。

我们可以
在免疫前取一点点婴儿血,免疫

后取一点点

,我们可以测量那一滴血
中所有细胞

、所有基因和所有分子
的库存,

我们可以 比较

同一婴儿的疫苗接种后和疫苗接种前的情况,

并深入

了解成功的疫苗是如何
保护的。

我们可以利用这些经验教训
在未来制造下一代疫苗。

所以这张图真的说明
了一小滴血会

产生大量信息,

数以万计的分析物,

而那个毛球是为了描绘
被打开的基因通路和被

打开的分子
通路。

还有很多事情要做,还有非常令人兴奋的科学。

因此,我们正在
与世界各地的科学家合作,利用

所有这些新技术来推动

精准疫苗网络中的疫苗开发。

我们将为世界各地的弱势群体推进
个性化疫苗

我们的团队包括科学家、
技术专家和医生。

我们正在开发
针对

百日咳等传染病的疫苗,也就是百日咳。

我们有百日咳

疫苗,但需要多次接种,

而且免疫力不断下降。

我们想开发一种单针
百日咳疫苗。

我们正在研制一种
呼吸道合胞病毒疫苗

,这是美国婴儿住院的头号原因。

一种更好的流感疫苗

,当然还有艾滋病毒。

我们还在研究
针对癌症、过敏

以及有趣的是阿片类药物过量的疫苗。

所以,这是我给你的最后一条信息。

疫苗可以保护您和您的亲人

和您周围的人。

它们不仅可以保护您
免受感染,

还可以防止您
将其传播给他人。

接种疫苗。

科学进步是脆弱的
,可能会丢失。

我们必须促进准确
和尊重的公开对话。

最后,我们正
处于伟大事物的边缘,

一个疫苗接种的新时代。

我们只是
触及了可以完成的事情的皮毛。

请倡导这项研究。

谢谢你。

(掌声)